US and Indian Pharmacopeias Collaborate on Drug Quality
The two pharmacopeias signed a Memorandum of Understanding as recognition of their collaboration for developing international science-based standards.
The US Pharmacopeial Convention (USP) announced on March 17, 2017 that it had signed a Memorandum of Understanding (MOU) with the Indian Pharmacopoeia Commission (IPC) in recognition of the two pharmacopeias’ collaboration in identifying and developing science-based standards. The two organizations have committed to working together to increase awareness of the importance of quality and safety of medications and safeguard the quality of and access to the drug supply chain.
USP and IPC have collaborated on projects in the past, and USP CEO Dr. Ronald T. Piervincenzi stated, in a press release, that he felt the MOU would be “a significant step forward in how two standard setting bodies can work together to improve global health through quality standards … Our collaboration will amplify the global public health impact of both organizations by leveraging our mutual scientific resources to advance international standards.”
Source: USP
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.
